News | Artificial Intelligence | January 23, 2023

Study analyzes more than 2,000 patient samples, confirming the technology delivers more accurate, objective, diagnostic data than traditional testing 

Capturing more information from every slide, stain, and tissue sample than humanly possible, artificial intelligence is used to hone in on a set of 8-12 key features specific to each disease.

Capturing more information from every slide, stain, and tissue sample than humanly possible, artificial intelligence is used to hone in on a set of 8-12 key features specific to each disease.


January 23, 2023 —  PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, announced its recent publication in Breast Cancer Research, demonstrating the ability of its digital AI platform to enrich breast cancer grading and improve risk categorization. The paper, titled 'Development and Validation of an AI-Enabled Digital Breast Cancer Assay to Predict Early-Stage Breast Cancer Recurrence Within 6 Years,' illustrates an industry-changing advancement in cancer diagnosis and outcome predictions. 

Despite advances in breast cancer screening and diagnosis, there continues to be an opportunity to significantly improve accuracy in histologic characterization, grading and prognosis. Once breast cancer is detected, pathologists and oncologists are tasked to set a course for an effective treatment plan which is currently limited by the subjectivity of a visual interpretation of the invasive disease.  

PreciseDx's Platform, which leverages its Morphology Feature Array, has proven the ability to enhance pathology interpretation with objective, quantifiable, and highly accurate data. This provides more robust information regarding patient disease status, representing the next generation of pathology analysis. 

"There still remains an inherent subjectiveness in the cancer classification, grading and prognosis," said PreciseDx CEO, Wayne Brinster. "Our platform was designed to set a new standard of information and accuracy without interrupting workflows. I am proud to lead an organization that is truly transforming the way cancer is staged and graded worldwide." 

The population-based longitudinal clinical development and validation study examined more than 2,000 patients from Mount Sinai Hospital with infiltrating ductal carcinoma of the breast. Following patients retrospectively for a median of six years, the study determined the PreciseDx Platform improved risk stratification and prediction of disease recurrence over standard histologic grade and clinical features and, furthermore, demonstrated the ability to supplement molecular genomic tests. 

"The recent publication in Breast Cancer Research on the clinical validation of our AI-enabled digital assay to predict early-stage breast cancer recurrence represents a key milestone in advancing our automated AI-driven platform to phenotype and grade invasive breast cancer with just an Hematoxylin and Eosin (H&E) image and readily available clinical data," said Michael Donovan, MD, PhD, Co-Founder and Chief Medical Officer at PreciseDx. "Additional extended validation studies are underway to enrich our current results and ultimately broaden access to this platform throughout the breast cancer community." 

For more information: https://precisedx.ai/ 


Related Content

News | Magnetic Resonance Imaging (MRI)

June 7, 2023 — GE HealthCare announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based ...

Time June 07, 2023
arrow
News | Radiology Business

June 6, 2023 — RaySearch Laboratories has announced that New York University (NYU) Langone Hospital - Long Island ...

Time June 06, 2023
arrow
News | Radiation Oncology

June 5, 2023 — Volpara Health Technologies Ltd. announces its founding membership in CancerX, a public-private ...

Time June 05, 2023
arrow
News | Linear Accelerators

June 5, 2023 — UMC Utrecht researchers in the Netherlands are starting two new projects to treat cancer with image ...

Time June 05, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

June 2, 2023 — Philips has entered into a collaboration with medical imaging company Polarean to advance the field of ...

Time June 02, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

June 2, 2023 — Ezra, the healthcare artificial intelligence (AI) startup transforming early cancer detection through ...

Time June 02, 2023
arrow
Feature | Radiology Imaging | By Melinda Taschetta-Millane

It's been a fruitful month for itnonline.com! Here's a look at what ITN viewers found to be most interesting during the ...

Time June 01, 2023
arrow
News | Radiation Therapy

May 30, 2023 — The first treatment, for a patient with prostate cancer, was successfully carried out on April 28. Yonsei ...

Time May 30, 2023
arrow
News | Radiology Business

May 26, 2023 — HIMSS has appointed two technology executives at the helm as chair and vice chair of the HIMSS Board of ...

Time May 26, 2023
arrow
News | Computed Tomography (CT)

May 26, 2023 — GE HealthCare, a leading medical technology innovator, announced today its largest ever CT deal in the ...

Time May 26, 2023
arrow
Subscribe Now